JP7769176B2 - 腸内細菌胆汁酸代謝の小分子モジュレーター - Google Patents

腸内細菌胆汁酸代謝の小分子モジュレーター

Info

Publication number
JP7769176B2
JP7769176B2 JP2021567062A JP2021567062A JP7769176B2 JP 7769176 B2 JP7769176 B2 JP 7769176B2 JP 2021567062 A JP2021567062 A JP 2021567062A JP 2021567062 A JP2021567062 A JP 2021567062A JP 7769176 B2 JP7769176 B2 JP 7769176B2
Authority
JP
Japan
Prior art keywords
cancer
disease
compound
substituted
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021567062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533069A (ja
JP2022533069A5 (https=
Inventor
デブリン，アビゲイル，スローン
アジカリ，アリジット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2022533069A publication Critical patent/JP2022533069A/ja
Publication of JP2022533069A5 publication Critical patent/JP2022533069A5/ja
Priority to JP2025141993A priority Critical patent/JP2026000925A/ja
Application granted granted Critical
Publication of JP7769176B2 publication Critical patent/JP7769176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021567062A 2019-05-10 2020-05-08 腸内細菌胆汁酸代謝の小分子モジュレーター Active JP7769176B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141993A JP2026000925A (ja) 2019-05-10 2025-08-28 腸内細菌胆汁酸代謝の小分子モジュレーター

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962846457P 2019-05-10 2019-05-10
US62/846,457 2019-05-10
US202062962048P 2020-01-16 2020-01-16
US62/962,048 2020-01-16
PCT/US2020/032016 WO2020231776A1 (en) 2019-05-10 2020-05-08 Small molecule modulators of gut bacterial bile acid metabolism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141993A Division JP2026000925A (ja) 2019-05-10 2025-08-28 腸内細菌胆汁酸代謝の小分子モジュレーター

Publications (3)

Publication Number Publication Date
JP2022533069A JP2022533069A (ja) 2022-07-21
JP2022533069A5 JP2022533069A5 (https=) 2023-05-16
JP7769176B2 true JP7769176B2 (ja) 2025-11-13

Family

ID=73289482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567062A Active JP7769176B2 (ja) 2019-05-10 2020-05-08 腸内細菌胆汁酸代謝の小分子モジュレーター
JP2025141993A Pending JP2026000925A (ja) 2019-05-10 2025-08-28 腸内細菌胆汁酸代謝の小分子モジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141993A Pending JP2026000925A (ja) 2019-05-10 2025-08-28 腸内細菌胆汁酸代謝の小分子モジュレーター

Country Status (9)

Country Link
US (1) US12577273B2 (https=)
EP (1) EP3965748A4 (https=)
JP (2) JP7769176B2 (https=)
KR (2) KR20250171471A (https=)
CN (2) CN120757601A (https=)
AU (1) AU2020274319B2 (https=)
BR (1) BR112021022431A2 (https=)
CA (1) CA3137308A1 (https=)
WO (1) WO2020231776A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
IT202200008861A1 (it) * 2022-05-03 2023-11-03 Chemelectiva S R L Processo per la preparazione di derivati dell’acido colico.
CN115337312B (zh) * 2022-08-19 2025-06-03 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途
CN118021751A (zh) * 2024-01-15 2024-05-14 中国人民解放军总医院第五医学中心 一种免疫调节的口服微球、制备方法及应用
US20250299939A1 (en) * 2024-03-25 2025-09-25 Thermo Finnigan Llc Calibration of an Image Current-based Mass Analyzer Included in a Mass Spectrometer
WO2025235593A1 (en) * 2024-05-09 2025-11-13 The Regents Of The University Of California Treatment for obstructive sleep apnea-associated atherosclerosis
CN119565571B (zh) * 2024-10-17 2025-11-21 湖北省食品质量安全监督检验研究院(湖北食品、保健食品、化妆品质量安全检测中心) 一种不溶性吸附除氟复合材料颗粒及其制备方法、应用和除氟包
CN119950519B (zh) * 2025-01-07 2025-11-21 山东省海洋科学研究院(青岛国家海洋科学研究中心) 奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075365A1 (en) 2017-10-13 2019-04-18 Battelle Memorial Institute PROBE FOR BSH (BILE SALT HYDROLASE), ITS PREPARATION AND USE METHOD

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360354A (en) 1972-01-20 1974-07-17 Union International Co Ltd Chenodeoxycholic acid
JPS5826360B2 (ja) 1974-08-23 1983-06-02 エ−ザイ カブシキガイシヤ グリコケノデオキシコ−ルサンノ セイホウ
IT1221734B (it) 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5210272A (en) 1990-02-16 1993-05-11 Prototek, Inc. Process for forming a fluoromethyl ketone
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
NZ245504A (en) 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
IT1255450B (it) 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
IT1270853B (it) 1993-05-20 1997-05-13 Sanofi Elf Procedimento per la preparazione di derivati taurocolanici
EP0717631B1 (en) 1993-09-09 2003-07-09 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US5695738A (en) 1995-06-15 1997-12-09 Glycomed Incorporated Steroidal C-glycosides
US5763435A (en) 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
CA2206047A1 (en) 1997-05-23 1998-11-23 Romeo Rang (Deceased) Immunomodulating compositions for the treatment of viral disorders
DE19849722A1 (de) 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1187364C (zh) 1999-04-30 2005-02-02 亚其发展公司 类固醇衍生物
DE19941764A1 (de) 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
SK3862002A3 (en) 1999-09-22 2003-01-09 Aventis Pharma Gmbh 4-Benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
US6451355B1 (en) 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
ITTO20020102A1 (it) 2002-02-06 2003-08-06 Abc Ist Biolog Chem Spa Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
ITMI20030822A1 (it) 2003-04-18 2004-10-19 Erregierre Spa Processo per la preparazione dell'acido ursodesossicolico
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
CA2608052A1 (en) 2005-05-10 2006-11-16 Laboratoires Fournier S.A. Novel use of liver x receptor agonists
US9295677B2 (en) 2008-02-26 2016-03-29 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
CA2758023A1 (en) 2008-04-09 2009-10-15 Cornell University Commensal bacteria as signal mediators within a mammalian host
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
WO2012151252A2 (en) 2011-05-02 2012-11-08 Biokier, Inc. Composition and method for treatment of diabetes
IT1393095B1 (it) 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
EP2470553B1 (en) 2009-08-25 2024-06-19 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
CA2859965A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
WO2013113680A1 (en) 2012-02-03 2013-08-08 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
US9580459B2 (en) 2013-04-26 2017-02-28 Metselex, Inc. Water-soluble ursodeoxycholic acid prodrugs
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
US20190125745A1 (en) 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
AR103260A1 (es) * 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
TW201704251A (zh) * 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 鵝去氧膽酸衍生物
EP3310801B1 (en) 2015-06-19 2021-04-07 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
TWI618714B (zh) * 2015-08-27 2018-03-21 中央研究院 涎酸轉移酶抑制劑及其用途
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
US20170233431A1 (en) 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
RU2665685C1 (ru) 2017-09-18 2018-09-04 Общество с ограниченной ответственностью "МДК Медика" Способ получения алкиламмонийных солей алкилсерных кислот
US20210122780A1 (en) 2018-03-29 2021-04-29 Metselex, Inc. Compositions for the prevention and treatment of parkinson's disease
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
WO2021226447A1 (en) 2020-05-08 2021-11-11 President And Fellows Of Harvard College Methods for inducing bile acid sulfotransferase sult2a for treating metabolic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075365A1 (en) 2017-10-13 2019-04-18 Battelle Memorial Institute PROBE FOR BSH (BILE SALT HYDROLASE), ITS PREPARATION AND USE METHOD

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. Biochem.，1938年，27，265-277
Steroids，1979年，34，171-187
Steroids，1995年，60，439-444
Steroids，1996年，61，421-428

Also Published As

Publication number Publication date
US20220204548A1 (en) 2022-06-30
EP3965748A4 (en) 2023-02-01
CN114641280A (zh) 2022-06-17
WO2020231776A8 (en) 2021-05-14
US12577273B2 (en) 2026-03-17
BR112021022431A2 (pt) 2022-05-24
WO2020231776A1 (en) 2020-11-19
CN120757601A (zh) 2025-10-10
CN114641280B (zh) 2025-05-27
KR20250171471A (ko) 2025-12-08
JP2022533069A (ja) 2022-07-21
AU2020274319A1 (en) 2021-12-02
EP3965748A1 (en) 2022-03-16
CA3137308A1 (en) 2020-11-19
KR102893599B1 (ko) 2025-12-01
JP2026000925A (ja) 2026-01-06
KR20220007112A (ko) 2022-01-18
AU2020274319B2 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
JP7769176B2 (ja) 腸内細菌胆汁酸代謝の小分子モジュレーター
US20250388562A1 (en) Small molecule degraders of helios and methods of use
TWI643855B (zh) Fxr (nr1h4) 調節化合物
TWI640520B (zh) Fxr (nr1h4) 調節化合物
EP3609888B1 (en) Farnesoid x receptor agonists and uses thereof
EP3019503B1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
EP3019499B1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
CA3005760C (en) Compounds and methods for inhibiting production of trimethylamine
US10745405B2 (en) Glucuronide prodrugs of Janus kinase inhibitors
TW201802086A (zh) Fxr (nr1h4) 調節化合物
CA2969803A1 (en) Isoxazole hydroxamic acid compounds as lpxc inhibitors
CN112805279A (zh) 异噁唑衍生物及其制备方法和用途
US10961231B2 (en) NTCP inhibitors
WO2015066413A1 (en) Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
US20210238225A1 (en) Peptidomimetic inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1)
BR122025012723A2 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, respectivos usos, método para inibir hidrolase do sal biliar (bsh) e kit
US20240239738A1 (en) (S)-3-AMINO-4-(DIFLUOROMETHYLENE)CYCLOHEXENE AND CYCLOHEXANE CARBOXYLIC ACID AND USES THEREOF AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE (hOAT)
TW201544494A (zh) 胰高血糖素樣肽第一型（ｇｌｐ－１）受體調控子及其於調節血糖濃度之用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250828

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

R150 Certificate of patent or registration of utility model

Ref document number: 7769176

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150